Scala Biodesign

Company Overview

Snapshot

Founded in March 2022 by Ravit Netzer and Adi Goldenzweig, Scala Biodesign operates with 11–50 employees. The company has raised $21.5 million across 2 funding rounds from 6 investors.

Business overview

Scala Biodesign develops advanced computational protein design solutions to tackle complex protein development challenges. The company's core technology accelerates the development process, enhances success rates, and reduces R&D efforts for proteins requiring stringent activity, shelf-life, and safety standards. Scala Biodesign serves the pharmaceutical, chemical, diagnostics, and food sectors, operating within the Health Tech & Life Sciences sector, specifically focusing on Drugs Discovery & Development.

Strategic signal

In March 2026, Scala Biodesign announced new funding, highlighting its continued momentum in the computational protein design space. This development signals ongoing investor confidence in the company's technology and its potential to significantly reduce the time and cost associated with protein engineering, a critical bottleneck in various industries from pharmaceuticals to sustainable chemical manufacturing.

Company Intelligence Q&A

When was Scala Biodesign founded?

Scala Biodesign was founded in March 2022 by Ravit Netzer and Adi Goldenzweig.

What is Scala Biodesign's primary focus?

Scala Biodesign focuses on developing cutting-edge computational protein design solutions to address complex protein development challenges in the pharmaceutical, chemical, diagnostics, and food sectors.

Which investors participated in Scala Biodesign's March 2026 funding round?

The March 2026 funding round for Scala Biodesign saw participation from.

What is the total capital raised by Scala Biodesign?

Scala Biodesign has raised a total of $21.5 million across 2 funding rounds.